ArticleDiscover oncology2025
An explainable machine learning model for predicting the risk of distant metastasis in intrahepatic cholangiocarcinoma: a population-based cohort study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDistant metastasis (DM) in intrahepatic cholangiocarcinoma (ICC) is associated with poor prognosis and significantly high mortality. Therefore, developing an effective early prediction method for DM risk is crucial for tailoring personalized treatment plans and improving patient outcomes.
methodsThis study included data from eligible ICC patients collected from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2021. Feature selection was performed using three methods, including least absolute shrinkage and selection operator (LASSO) regression, the Boruta algorithm, and recursive feature elimination (RFE). Eight machine learning (ML) algorithms were used to develop predictive models. Model performance was evaluated and compared using metrics such as the area under the receiver operating characteristic curve (AUC), area under the precision-recall curve (AUPRC), decision curve analysis (DCA), and calibration curves. The SHapley Additive exPlanations (SHAP) method was applied to rank feature importance and interpret the final model.
resultThis study included 8536 ICC patients, including 2816 (33%) with DM. The intersection results of the three feature selection methods identified 10 predictive factors. Among the 8 ML models, the gradient boosting machine (GBM) model achieved the highest AUC (0.802), AUPRC (0.571), and accuracy (0.713), as well as the lowest Brier score (0.177), indicating a comparatively robust overall performance. Calibration curves and DCA indicated that the GBM model has good clinical decision-making capability and predictive performance. SHAP analysis identified the top 10 most relevant features, ranked by relative importance: surgery, N stage, tumor grade, T stage, tumor size, radiotherapy, tumor number, age at diagnosis, chemotherapy, and number of resected lymph nodes (LNs). Additionally, a web-based online calculator was developed to predict the risk of DM in ICC patients, available at https://bijinzhe.shinyapps.io/icc_dm_shiny/ .
conclusionThe GBM model demonstrated considerable potential in predicting the risk of DM in ICC patients. This could assist clinicians in formulating personalized treatment strategies, ultimately improving the overall prognosis of ICC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.